The IND application of Bozhiyan's new anti-tumor drug BCM323 oral solution was accepted by CDE!

On February 10, 2022, the IND application for the new drug project BCM323 oral solution of Shanghai Bozhiyan New Drug Technology Co.

BCM 323 Oral Liquid Project Introduction

BCM323 oral solution is a new me-better antitumor drug , registration classification 2.

BCM323 oral solution adopts polymer micelle solubilization technology to improve the solubility and permeability of active substances in the gastrointestinal tract, and at the same time selects excipients reasonably to inhibit the efflux of P-glycoprotein

SOL ENHANCED

Polymeric micelles are thermodynamically stable systems that spontaneously form when the concentration of amphiphilic polymers exceeds the critical micelle concentration (CMC)

Polymeric micelles have unique advantages:

① Increase the solubility of hydrophobic drugs;

② Stable physical and chemical properties;

③ Passive targeting, improve the biodistribution of drugs, improve bioavailability, and reduce toxic and side effects;

④ Physical encapsulation and chemical connection of drugs to increase drug loading and enhance therapeutic effect;

⑤ Flexible structure and multifunctional modification to achieve efficient drug delivery

Bozhiyanxin owns the leading solubilization delivery technology platform (SOL ENHANCED) in China, including micronization, complexes, inclusions, solid dispersions, lipid systems, microemulsions/self-microemulsions, surfactants and polymers Technologies such as micelles to enhance drug solubility and improve the bioavailability of poorly soluble drugs

The IND application of BociMed anti-tumor drug BCM323 oral solution was accepted by CDE!

10 February 2022, the IND application of the new drug project BCM323 oral solution of BociMed was accepted by the National Center for Drug Evaluation (acceptance number: CXHL2200086), mainly used for the treatment of various solid tumors.

BCM323 Oral Liquid

BCM323 oral solution is a new me-better anti-tumor drug, which is classified as 2.

BCM323 oral solution adopts polymer micelle solubilization technology to improve the solubility and permeability of active pharmaceutical ingredient in the gastrointestinal tract, selects excipients reasonably to inhibit the efflux of P-glycoprotein.

SOL ENHANCED

Polymeric micelles are thermodynamically stable systems that spontaneously form when the concentration of amphiphilic polymers exceeds the critical micelle concentration .

Polymeric micelles have unique advantages:

① Increase the solubility of hydrophobic drugs;

② Stable physical and chemical properties;

③ Passive targeting, improve the biodistribution of drugs, improve bioavailability, and reduce toxic and side effects;

④ Physical encapsulation and chemical connection of drugs to increase drug loading and enhance therapeutic effect;

⑤ Flexible structure and multifunctional modification to achieve efficient drug delivery.

BociMed owns the leading solubilization and delivery technology platform (SOL ENHANCED) in China, mastering the fields of micronization, complexes, inclusions, solid dispersions, lipid systems, microemulsions/self-emulsions, surfactants and polymer micelles, etc.

About Bozhiyanxin

Bozhiyanxin is a leading drug delivery technology platform enterprise, specializing in complex pharmaceutical preparations (sustained and controlled release preparations, bilayer and multi-layer preparations, long-acting injections), special pharmaceutical preparations (oral instant preparations, patches, nasal sprays, Pediatric preparations), solubilized pharmaceutical preparations (spray drying, nanocrystals, self-microemulsions, inclusion, micellar solubilization), highly active pharmaceutical preparations (HP DP), biological delivery technologies (exosomes, liposomes), etc.

business contact

Switchboard: 400-855-9019

Address: Building 1, Lane 647, Songtao Road, Pudong New Area, Shanghai